Literature DB >> 27076929

Clinical characteristics and risk factors of pulmonary hypertension associated with chronic respiratory diseases: a retrospective study.

Yonghua Chen1, Chunli Liu1, Wenju Lu1, Mengxi Li1, Cyrus Hadadi1, Elizabeth Wenqian Wang1, Kai Yang1, Ning Lai1, Junyi Huang1, Shiyue Li1, Nanshan Zhong1, Nuofu Zhang1, Jian Wang1.   

Abstract

BACKGROUND: Chronic respiratory disease-associated pulmonary hypertension (PH) is an important subtype of PH, which lacks clinical epidemiological data in China.
METHODS: Six hundred and ninety three patients hospitalized from 2010 to 2013 were classified by echocardiography according to pulmonary arterial systolic pressure (PASP): mild (36≤ PASP <50 mmHg); moderate (50≤ PASP <70 mmHg) and severe (PASP ≥70 mmHg).
RESULTS: Dyspnea (93.51%) was the most common symptom. Hemoptysis observed in the severe group (6.42%) was significantly higher than the other two groups (P<0.05). COPD (78.35%), lung bullae (44.16%), tuberculosis (including obsolete pulmonary tuberculosis) (38.82%), and bronchiectasis (30.45%) were frequently present. Mild group occupied the highest proportion (84.7%) in COPD, while severe group occupied the highest proportion (19.3%) in pulmonary embolism (P<0.01). Age, partial pressure of oxygen (PaO2), hematocrit (HCT), partial pressure of carbon dioxide (PaCO2), increase of N-terminal pro brain natriuretic peptide (NT-proBNP) and right ventricular (RV) diameter (>20 mm) were associated with moderate-to-severe PH, while RV [odds ratio (OR) =3.53, 95% CI, 2.17-5.74], NT-proBNP (OR=2.44, 95% CI, 1.51-3.95), HCT (OR=1.03, 95% CI, 1.00-1.07) and PaCO2 (OR=1.01, 95% CI, 1.00-1.03) were independent risk factors.
CONCLUSIONS: PH related to respiratory diseases is mostly mild to moderate, and the severity is associated with the category of respiratory disease. Increased HCT can be an independent risk factor for PH related to chronic respiratory diseases.

Entities:  

Keywords:  Pulmonary hypertension; clinical features; respiratory diseases; risk factors

Year:  2016        PMID: 27076929      PMCID: PMC4805801          DOI: 10.21037/jtd.2016.02.58

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN: 2072-1439            Impact factor:   2.895


  26 in total

Review 1.  Pulmonary hypertension: echocardiographic assessment.

Authors:  Susanna Sciomer; Roberto Badagliacca; Francesco Fedele
Journal:  Ital Heart J       Date:  2005-10

Review 2.  Pulmonary arterial hypertension.

Authors:  Harrison W Farber; Joseph Loscalzo
Journal:  N Engl J Med       Date:  2004-10-14       Impact factor: 91.245

3.  Severe pulmonary hypertension and chronic obstructive pulmonary disease.

Authors:  Ari Chaouat; Anne-Sophie Bugnet; Nabila Kadaoui; Roland Schott; Irina Enache; Alain Ducoloné; May Ehrhart; Romain Kessler; Emmanuel Weitzenblum
Journal:  Am J Respir Crit Care Med       Date:  2005-04-14       Impact factor: 21.405

4.  Hematocrit and the risk of coronary heart disease: the Honolulu Heart Program.

Authors:  C Carter; D McGee; D Reed; K Yano; G Stemmermann
Journal:  Am Heart J       Date:  1983-04       Impact factor: 4.749

5.  The significance of elevated brain natriuretic peptide levels in chronic obstructive pulmonary disease.

Authors:  E Bozkanat; E Tozkoparan; O Baysan; O Deniz; F Ciftci; M Yokusoglu
Journal:  J Int Med Res       Date:  2005 Sep-Oct       Impact factor: 1.671

Review 6.  [Heart pathology of extracardiac origin. IV. Pulmonary hypertension in chronic respiratory diseases].

Authors:  J A Barberà
Journal:  Rev Esp Cardiol       Date:  1998-01       Impact factor: 4.753

7.  Ischaemic heart disease: association with haematocrit in the British Regional Heart Study.

Authors:  G Wannamethee; A G Shaper; P H Whincup
Journal:  J Epidemiol Community Health       Date:  1994-04       Impact factor: 3.710

8.  Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT).

Authors:  Nazzareno Galiè; Marius M Hoeper; Marc Humbert; Adam Torbicki; Jean-Luc Vachiery; Joan Albert Barbera; Maurice Beghetti; Paul Corris; Sean Gaine; J Simon Gibbs; Miguel Angel Gomez-Sanchez; Guillaume Jondeau; Walter Klepetko; Christian Opitz; Andrew Peacock; Lewis Rubin; Michael Zellweger; Gerald Simonneau
Journal:  Eur Heart J       Date:  2009-08-27       Impact factor: 29.983

9.  Plasma brain natriuretic peptide as a noninvasive marker for efficacy of pulmonary thromboendarterectomy.

Authors:  Noritoshi Nagaya; Motomi Ando; Hideo Oya; Yutaka Ohkita; Shingo Kyotani; Fumio Sakamaki; Norifumi Nakanishi
Journal:  Ann Thorac Surg       Date:  2002-07       Impact factor: 4.330

10.  Primary pulmonary hypertension. A national prospective study.

Authors:  S Rich; D R Dantzker; S M Ayres; E H Bergofsky; B H Brundage; K M Detre; A P Fishman; R M Goldring; B M Groves; S K Koerner
Journal:  Ann Intern Med       Date:  1987-08       Impact factor: 25.391

View more
  5 in total

1.  Renal cell carcinoma: predicting RUNX3 methylation level and its consequences on survival with CT features.

Authors:  Dongzhi Cen; Li Xu; Siwei Zhang; Zhiguang Chen; Yan Huang; Ziqi Li; Bo Liang
Journal:  Eur Radiol       Date:  2019-03-15       Impact factor: 5.315

2.  Associations of Clinical Characteristics and Intestinal Flora Imbalance in Stable Chronic Obstructive Pulmonary Disease (COPD) Patients and the Construction of an Early Warning Model.

Authors:  Xuetao Zeng; Hongfeng Yang; Yan Yang; Xinnan Gu; Xiuqin Ma; Taofeng Zhu
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2021-12-18

3.  Statins for the Treatment of Pulmonary Hypertension in Patients with Chronic Obstructive Pulmonary Disease.

Authors:  Chung-Yu Chen; Wen-Ting Wu; Ya-Ling Wang; Kuang-Ming Liao
Journal:  Front Pharmacol       Date:  2021-01-08       Impact factor: 5.810

4.  Development of an Electronic Frailty Index for Predicting Mortality and Complications Analysis in Pulmonary Hypertension Using Random Survival Forest Model.

Authors:  Jiandong Zhou; Oscar Hou In Chou; Ka Hei Gabriel Wong; Sharen Lee; Keith Sai Kit Leung; Tong Liu; Bernard Man Yung Cheung; Ian Chi Kei Wong; Gary Tse; Qingpeng Zhang
Journal:  Front Cardiovasc Med       Date:  2022-07-08

5.  Characteristics of Chronic Obstructive Pulmonary Disease Patients with Pulmonary Hypertension Assessed by Echocardiography in a Three-Year Observational Cohort Study.

Authors:  Shingo Nakayama; Shotaro Chubachi; Kaori Sakurai; Hidehiro Irie; Akihiro Tsutsumi; Mizuha Hashiguchi; Yuji Itabashi; Mitsushige Murata; Hidetoshi Nakamura; Koichiro Asano; Koichi Fukunaga
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2020-03-03
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.